
|Videos|July 21, 2011
Dr. Tsimberidou on the Personalized Medicine Results
Author(s)Apostolia Tsimberidou, MD, PhD
Dr. Apostolia M. Tsimberidou from MD Anderson Cancer Center on the Personalized Medicine Study Results
Advertisement
Lead author Apostolia M. Tsimberidou, MD, PhD, of the University of Texas MD Anderson Cancer Center, believes that personalized medicine is the future of cancer care and focused on it in a phase I clinical trial conducted at MD Anderson Cancer Center.
The study examined cancer molecular analysis and used matched targeted therapy unique to the aberrations found in the analysis as a way to improve the outcomes of patients. The trial demonstrated that looking at particular genetic abnormalities to select treatment is associated with improved outcomes overall.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































